Milestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management
Milestone Scientific (NYSE:MLSS), developer of computerized drug delivery instruments, has appointed Dr. Dawood Sayed to its Board of Directors. Dr. Sayed, a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center, brings extensive expertise in interventional pain medicine and neuromodulation.
The appointment strengthens the company's clinical and commercial strategy for its CompuFlo® Epidural System, which recently received Medicare Part B payment coverage under CPT® code 0777T. Dr. Sayed's experience with health system adoption, clinical training, and reimbursement strategy is expected to accelerate MLSS's growth in the interventional pain management market.
Milestone Scientific (NYSE:MLSS), sviluppatore di strumenti di somministrazione di farmaci computerizzati, ha nominato il Dr. Dawood Sayed al suo Consiglio di Amministrazione. Il Dr. Sayed, Professore di Anestesia e Medicina del Dolore presso il University of Kansas Medical Center, porta una vasta competenza in medicina del dolore interventistica e neuromodulazione.
L’ingresso rafforza la strategia clinica e commerciale dell’azienda per il CompuFlo® Epidural System, che di recente ha ottenuto la copertura di pagamento Medicare Part B sotto il codice CPT® 0777T. L’esperienza del Dr. Sayed con l’adozione nei sistemi sanitari, la formazione clinica e la strategia di rimborso dovrebbero accelerare la crescita di MLSS nel mercato della gestione del dolore interventivo.
Milestone Scientific (NYSE:MLSS), desarrollador de instrumentos de administración de fármacos computarizados, ha nombrado al Dr. Dawood Sayed a su Junta Directiva. El Dr. Sayed, Profesor de Anestesiología y Medicina del Dolor en el University of Kansas Medical Center, aporta amplia experiencia en medicina del dolor intervencionista y neuromodulación.
El nombramiento fortalece la estrategia clínica y comercial de la empresa para su CompuFlo® Epidural System, que recientemente recibió cobertura de pago de Medicare Parte B bajo el código CPT® 0787T. Se espera que la experiencia del Dr. Sayed en adopción de sistemas de salud, formación clínica y estrategia de reembolso acelere el crecimiento de MLSS en el mercado de gestión del dolor intervencionista.
Milestone Scientific (NYSE:MLSS), 컴퓨터화된 약물 전달 기구를 개발하는 기업은 이사회에 다우드 사이드 박사를 임명했습니다. 사이드 박사는 캔자스 대학교 메디컬 센터의 마취학 및 통증의학 교수로, 인터벤션 통증 의학 및 신경자극에 대한 광범위한 전문 지식을 제공합니다.
이번 임명은 CompuFlo® Epidural System에 대한 회사의 임상 및 상업 전략을 강화하며, 이 시스템은 최근 CPT® 코드 0777T 아래 메디케어 파트 B 비용 보장을 받았습니다. 사이드 박사의 체계 도입, 임상 교육 및 상환 전략에 대한 경험은 MLSS의 인터벤션 통증 관리 시장에서의 성장을 가속화할 것으로 기대됩니다.
Milestone Scientific (NYSE:MLSS), développeur d'instruments de délivrance de médicaments informatisés, a nommé le Dr Dawood Sayed au conseil d'administration. Le Dr Sayed, professeur d'anesthésiologie et de médecine de la douleur au University of Kansas Medical Center, apporte une vaste expertise en médecine de la douleur interventionnelle et en neuromodulation.
Cette nomination renforcera la stratégie clinique et commerciale de l'entreprise pour son CompuFlo® Epidural System, qui a récemment obtenu une couverture de paiement Medicare Part B sous le code CPT® 0777T. L'expérience du Dr Sayed dans l'adoptionpar les systèmes de santé, la formation clinique et la stratégie de remboursement devrait accélérer la croissance de MLSS sur le marché de la gestion de la douleur interventionnelle.
Milestone Scientific (NYSE:MLSS), Entwickler computergestützter Arzneimittelabgabesysteme, hat Dr. Dawood Sayed in das Board of Directors berufen. Dr. Sayed, Professor für Anästhesiologie und Schmerzmedizin am University of Kansas Medical Center, bringt umfassende Expertise in interventioneller Schmerzmedizin und Neuromodulation mit.
Die Berufung stärkt die klinische und kommerzielle Strategie des Unternehmens für sein CompuFlo® Epidural System, das kürzlich eine Medicare Part B-Zahlungsdeckung unter dem CPT®-Code 0777T erhalten hat. Die Erfahrung von Dr. Sayed mit der Einführung in Gesundheitssysteme, klinischer Schulung und Abrechnungsstrategie soll das Wachstum von MLSS im Markt der interventionellen Schmerztherapie beschleunigen.
قامت Milestone Scientific (NYSE:MLSS)، مطوّر أجهزة توصيل الدواء المحوسبة، بتعيين الدكتور داوود سيد عضوًا في مجلس الإدارة. الدكتور سيد، أستاذ التخدير وطب الألم في مركز جامعة كانساس الطبي، يجلب خبرة واسعة في طب الألم التدخلي والتنبيه العصبي.
يعزز التعيين استراتيجية الشركة السريرية والتجارية لـ CompuFlo® Epidural System، والذي تلقى مؤخرًا تغطية من ميديكير Part B بموجب الرمز CPT® 0777T. من المتوقع أن تُسرع خبرة الدكتور سيد في اعتماد الأنظمة الصحية والتدريب السريري واستراتيجيات السداد من نمو MLSS في سوق إدارة الألم التدخلي.
Milestone Scientific (NYSE:MLSS)，是一家开发电脑化药物递送仪器的公司，现任命多伍德·赛义德博士为董事会成员。赛义德博士是堪萨斯大学医学中心麻醉学与疼痛医学教授，在介入性疼痛医学和神经调控方面具有丰富专长。
此次任命将加强公司在其CompuFlo® Epidural System的临床与商业策略，该系统最近已获得 Medicare Part B 付款覆盖，编码为 CPT® 0777T。赛义德博士在卫生系统采纳、临床培训和报销策略方面的经验，预计将加速 MLSS 在介入性疼痛管理市场的增长。
- None.
- None.
Insights
Dr. Sayed's appointment strengthens Milestone Scientific's clinical credibility and market strategy for CompuFlo's expansion in interventional pain management.
The addition of Dr. Dawood Sayed to Milestone Scientific's Board represents a strategic enhancement to the company's clinical and commercial capabilities in the interventional pain management sector. As a Professor of Anesthesiology, Division Chief of Pain Medicine, and leader in neuromodulation at the University of Kansas Medical Center, Dr. Sayed brings valuable expertise that directly aligns with Milestone's growth strategy for its CompuFlo® technology.
This appointment completes Milestone's initiative to strengthen its Board with medical expertise, which is particularly significant as the company navigates the critical commercialization phase for CompuFlo®. The technology's recent assignment of a Medicare Part B payment rate under CPT® code 0777T in several jurisdictions marks an important reimbursement milestone that could accelerate market adoption.
Dr. Sayed's extensive involvement in pain medicine policy through organizations like the American Society of Pain and Neuroscience (ASPN) and his relationships with commercial payers could prove instrumental in addressing one of the primary barriers to medical device adoption – reimbursement. His experience leading clinical trials and developing treatment guidelines positions the company to better navigate the evidence requirements typically demanded by payers.
From a commercial strategy perspective, this appointment signals Milestone's focus on transitioning from technology development to market expansion, with particular emphasis on physician adoption and payer coverage. The company appears to be building momentum through a combination of clinical validation, reimbursement progress, and now enhanced board-level expertise in their specific therapeutic area.
Appointment strengthens Board expertise as Milestone Scientific drives commercial expansion and payer adoption of CompuFlo® in interventional pain management
ROSELAND, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dawood Sayed, M.D., a nationally recognized leader in interventional pain medicine, to its Board of Directors, effective immediately.
Dr. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and currently serves as Division Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. With a robust clinical, academic, and policy background, he brings over a decade of leadership in pioneering minimally invasive pain therapies, neuromodulation, and health system innovation.
Dr. Sayed also serves as Vice Chairman and Co-Founder of the American Society of Pain and Neuroscience (ASPN), where he works closely with key stakeholders, including commercial payers, regulators, and medical device manufacturers to advance access to innovative pain relief technologies. His leadership has earned him multiple honors, including the 2025 Presidential Award from the North American Neuromodulation Society (NANS).
“We are honored to welcome Dr. Sayed to the Milestone Scientific Board,” stated Neal Goldman, Chairman of Milestone Scientific. “His deep expertise in pain medicine and strong relationships across the clinical and payer communities will be instrumental as we expand adoption of CompuFlo® across pain management and spine intervention markets. With this appointment, we complete our strategic initiative to bring prominent medical voices to the Board, ensuring that Milestone remains aligned with the evolving needs of patients, physicians, and payers.”
Milestone Scientific’s CompuFlo® Epidural System is a groundbreaking platform technology that precisely identifies the epidural space with real-time pressure feedback, offering a safer and more reliable alternative to traditional loss-of-resistance techniques. The technology has been increasingly validated by clinical leaders and was recently assigned a Medicare Part B payment rate under CPT® code 0777T in several jurisdictions. Early activity from commercial insurers also indicates growing interest in supporting technologies that reduce procedural risk and improve outcomes.
“Dr. Sayed’s appointment is a significant step forward in our commitment to build a clinically informed, market-driven organization,” commented Eric Hines, Chief Executive Officer of Milestone Scientific. “As we move into the next phase of commercial growth, his knowledge of health system adoption, clinical training, and reimbursement strategy will help accelerate our penetration into the interventional pain management space.”
“I am excited to join Milestone Scientific’s Board at a time when innovation in interventional pain care is critical to improving patient outcomes and reducing opioid reliance,” said Dr. Sayed. “CompuFlo® is a truly disruptive technology that addresses a long-standing challenge in spinal procedures. I look forward to working with the team to drive greater clinical adoption and improve procedural safety.”
Dr. Sayed has authored over 100 peer-reviewed publications, contributed to national guidelines in pain medicine, and currently leads multiple clinical trials evaluating neuromodulation and spinal therapies. He also serves as a medical advisor to several leading medtech innovators and participates on national AMA CPT® and NANS advocacy committees.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient, and increase the overall patient comfort and safety. The Company leverages its proprietary DPS Dynamic Pressure Sensing Technology® platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetics. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ
Who is Dr. Dawood Sayed and why did Milestone Scientific (MLSS) appoint him to the Board?
What is Milestone Scientific's (MLSS) CompuFlo® Epidural System?
Has Medicare approved coverage for MLSS's CompuFlo® System?
What is Dr. Sayed's experience in pain management?
How will Dr. Sayed's appointment benefit Milestone Scientific (MLSS)?
